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Abstract
The aetiology of osteoporotic fractures is multifactorial, but little is known about the way to evaluate
patients with a recent clinical fracture for the presence of secondary osteoporosis.
The purpose of this study was to determine the prevalence of contributors to secondary osteoporosis in
patients presenting with a clinical vertebral or non-vertebral fracture. Identifying and correcting these
contributors will enhance treatment effect aimed at reducing the risk of subsequent fractures.
In a multidisciplinary approach, including evaluation of bone and fall-related risk factors, 100 consecutive
women (n = 73) and men (n = 27) older than 50 years presenting with a clinical vertebral or non-vertebral
fracture and having osteoporosis (T-score ≤-2.5) were further evaluated clinically and by laboratory testing
for the presence of contributors to secondary osteoporosis.
In 27 patients, 34 contributors were previously known, in 50 patients 52 new contributors were diagnosed
(mainly vitamin D deficiency in 42) and 14 needed further exploration because of laboratory abnormalities
(mainly abnormal thyroid stimulating hormone in 9). The 57 patients with contributors were older (71 vs.
64 yrs, p < 0.01), had more vertebral deformities (67% vs. 44%, p < 0.05) and a higher calculated absolute
10-year risk for major (16.5 vs. 9.9%, p < 0.01) and for hip fracture (6.9 vs. 2.4%, p < 0.01) than patients
without contributors. The presence of contributors was similar between women and men and between
patients with fractures associated with a low or high-energy trauma.
We conclude that more than one in two patients presenting with a clinical vertebral or non-vertebral
fracture and BMD-osteoporosis have secondary contributors to osteoporosis, most of which were
correctable. Identifying and correcting these associated disorders will enhance treatment effect aimed at
reducing the risk of subsequent fractures in patients older than 50 years.
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Background
Clinical vertebral and non-vertebral fractures are the most
frequent fractures in patients presenting to the emergency
ward of the hospital with a fracture [1]. After such fracture,
patients are at increased risk for subsequent fracture and
guidelines on osteoporosis advocate to evaluate patients
presenting with a fracture in order to consider treament to
reduce the risk of subsequent fractures [2].
One aspect of care identified within the management of
fracture patients is the existence of contributors to second-
ary causes of bone loss [3]. Effective therapy requires that
these contributors be recognised and when present man-
aged appropriately [3,4]. If these conditions, however, are
not recognized, treatment may be suboptimal or ineffec-
tive [5,6].
Apart from bone mineral density (BMD)-osteoporosis (T-
score less than or equal to -2.5) [4,7,8] many risk factors
are related to fracture risk, independently of BMD, such as
clinical risk factors [9], fall risks [10], prevalent morpho-
metric vertebral fractures (MVF) [11] and secondary oste-
oporosis [12]. There is increasing evidence that secondary
osteoporosis is more prevalent than initially thought, not
only in males, but also in females [13], but the true prev-
alence of contributors to secondary osteoporosis is
unknown and no consensus regarding its evaluation is
available [14].
Published data from referral centres for evaluation of oste-
oporosis indicate that 32 to 37% of women with low
BMD have a history of other diseases or medications
known to contribute to osteoporosis [3,15]. From 20% up
to 64% of patients had previously unknown secondary
causes of osteoporosis that were only identified by labora-
tory testing [5]. In a study of patients with a clinical frac-
ture, a high prevalence of contributors to secondary
osteoporosis (77%) was reported, but the study included
only a limited number of patients with measured low
BMD [16]. In a study of patients with a hip fracture, 80%
had secondary causes of bone loss, mainly related to dis-
turbed calcium and vitamin D homeostasis [6]. To date,
we lack studies on the prevalence of contributors to sec-
ondary osteoporosis in other fracture populations.
The purpose of this study was to determine the prevalence
of contributors to secondary osteoporosis, in the context
of other bone- and fall-related fracture risks in patients
presenting with a clinical vertebral or non-vertebral frac-
ture and with a low BMD. Identifying and correcting con-
tributors will enhance treatment effect aimed at reducing
the risk of subsequent fractures.
Methods
In this prospective observational study, 100 consecutive
and consenting patients older than 50 years, who pre-
sented between April 2005 and April 2006 with a clinical
fracture at Maastricht University Hospital in the Nether-
lands, were included. After receiving medical treatment
for the fracture, patients had a consultation with the frac-
ture nurse. The fracture nurse provided information about
the study and invited the patients to the Fracture and
Osteoporosis Outpatient Clinic. Patients already on oste-
oporosis treatment (44/1246, 4% of all) or with patholog-
ical fractures due to malignancy or Paget's disease of bone
were excluded from the analysis. Patients who agreed to
participate were further referred to the program. Patients
with osteoporosis according to World Health Organiza-
tion (WHO) criteria for BMD [4] and in whom all labora-
tory data were available were included in the present study
(Figure 1). This group was part of the evaluation of all
consecutive patients presenting with a clinical fracture, of
whom 35% had osteoporosis and 44% had osteopenia
[1]. The medical ethical committee of the University Hos-
pital Maastricht approved the study (MEC 03-194-5).
BMD in the left or right hip and the lumbar spine was
determined using dual X-ray absorptiometry (DXA) with
Hologic QDR 4500 Elite. Diagnosis of osteoporosis was
based on the WHO criteria for BMD [4], as provided by
the manufacturer for women and men. Patients were clas-
sified according to the lowest value of T-score in either
total hip or spine.
All patients were interviewed for bone-related risk factors
for fracture (previous non-vertebral and vertebral frac-
tures, mother with fracture, body weight <60 kg, severe
immobility, use of glucocorticoids) and fall-risk factors
(falls in the past 12 months, use of assistive devices, seda-
tive medication, activities of daily living, mobility,
impaired vision, articular complaints, urine inconti-
nency), according to the Dutch guidelines on osteoporo-
sis [2] and fall prevention [10]. Additionally, data about
vitamin D status (regular sun exposure, dietary intake and
supplements), calcium intake [17,18], height, history of
height loss [19] and a description of the circumstances
leading to the fracture (with specification of fall from a
standing height or other trauma) were recorded.
Patients with T-scores ≤-2.5 were given a pre-planned set
of laboratory tests that included erythrocyte sedimenta-
tion rate (ESR), haemoglobin, leucocytes and serum levels
of creatinine, calcium, albumin, alkaline phosphatase, 25-
OHD3 and TSH. Calcium and creatinine were measured in
a 24-hour urine collection. All laboratory analyses were
performed in the same laboratory. Patients with oste-
oporosis and having the full set of evaluation were sent for
a consultation with either a rheumatologist or an endo-BMC Musculoskeletal Disorders 2008, 9:109 http://www.biomedcentral.com/1471-2474/9/109
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crinologist. The specialist decided further investigation
and treatment. When clinically appropriate, additional
tests were performed. The diagnosis of contributors to sec-
ondary osteoporosis was based on all data from the med-
ical files. Renal insufficiency was defined with the cut-off
value of creatinine clearance ≤40 using the Cockroft Gault
formula [20]. Vitamin D status was defined as severely
deficient when values were ≤30 nmol/L, deficient when
between 30 and ≤50 nmol/L, insufficient when values
were between 50 and ≤75 nmol/L [21,22] and abnormally
high when above 220 nmol/L [23]. Exploration for
hypogonadism in men was considered when a morning
serum testosterone level was below 12 nmol/L [24] and
for thyroid disorders when TSH were outside the reference
ranges (0.4–3.5 mU/L). Hyperparathyroidism was diag-
nosed when serum parathyroid hormone (PTH) levels
were above 5.5 pmol/l. Further exploration for hypercalci-
uria was considered when the total urinary calcium in a 24
hours collection exceeded 7 mmol/d and creatinuria indi-
cated an appropriate collection (between 4.5 – 13.3
Flow chart of patients included in the study (see text for details) in one year Figure 1
Flow chart of patients included in the study (see text for details) in one year.
233 patients not eligible 
(39 dead, 41 dementia, 93 other 
region, 44 already on treatment, 
16 pathological fractures) 
423 patients excluded 
(236 refused to participate,
169 no DXA appointment,
18 other) 
590 patients
Fracture and Osteoporosis 
Outpatient Clinic 
100 patients 
419 patients with normal 
BMD or osteopenia, 71 
had no vitamin D 
measurement 
1013 patients 
1246 patients
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mmol/hour) [25]. According to clinical judgement,
patients suspected to have lactose intolerance had a lac-
tose tolerance test [26].
Vertebral fracture assessment (VFA) [27,28] by single X-
ray absorptiometry on the lateral spine images was per-
formed to identify the presence of morphometric verte-
bral deformities (MVD). Images were saved in a digital
format. Physician Viewer software (Hologic, USA) pro-
vided the tools necessary to perform quantitative vertebral
morphometry. Visual assessment and measurements of
the anterior, posterior and mid heights from T4 to L4 were
performed twice, by a trained rheumatologist (BD). These
assessments were inputted into a database. The observer
was blinded from the results of the first measurements.
The intra-observer coefficient of variation (ICC) at verte-
bral level for heights was 0.917 (95% confidence interval
(CI): 0.905–0.930, Cronbach's alpha 0.959). The arith-
metic mean heights of the two measurements were used
for calculation. The anterior-posterior ratio, the middle-
posterior ratio, the posterior-posterior ratio were calcu-
lated. Prevalent morphometric vertebral deformities
(MVD) were defined according to the Genant grading
[29]. Vertebral deformities were classified into three types
(wedge, biconcavity, crush) and three grades (mild (any
ratio <20%), moderate (any ratio between 25–40%), and
severe (any ratio >40%)).
The WHO Fracture risk assessment tool (FRAX) was used
to calculate the absolute 10-year risk for major and for hip
fractures in women and men [12].
Statistical analyses were performed using SPSS version
12.01. Categorical variables and proportions were ana-
lyzed using chi-square statistic. Odds ratio (OR) with 95%
confidence intervals (95% CI) were calculated based on
the chi squares. One way Anova and chi-square statistics
were used to analyze differences in continuous variables
between subgroups. Observations were considered signif-
icant if two-sided p-values were < 0.05.
Results
Of the 100 patients, 73 were women and were 27 men.
Mean age was 68 years (standard deviation: 10 years,
range: 50 to 90 years). Demographic data are summarized
in Table 1. The majority of patients were Caucasian
(97%). Fractures were found at the following locations:
clinical vertebral fractures (n = 4), clavicle (n = 3), pelvis
(n = 2), humerus (n = 10), radius and/or ulna (n = 24),
hand (n = 6), hip (n = 17), tibia/fibula/patella (n = 8) and
foot (n = 21). Five patients had multiple simultaneous
fractures and 80 patients had fractures after a fall from
standing height.
A total of 86 contributors to secondary osteoporosis were
diagnosed in 57 patients (Table 1 and 2). Contributors
consisted of known medical conditions (34 in 27
patients) or newly diagnosed (52 in 50 patients). Seven
patients had only known contributors, 20 had known
plus a newly diagnosed contributor and 30 had only
newly diagnosed contributors. One contributor was
found in 32 (of whom 24 were vitamin D deficient), more
than one contributor in 25 and 43 had none.
Based on serum levels of 25-OHD3, 11 patients had severe
deficiency, 31 were deficient and 31 had insufficient
serum values. All were newly diagnosed. Serum levels of
25-OHD3 could not be predicted by any of questions on
vitamin D or by the sum of those questions. Calcium
intake below 1200 mg was reported in 86 patients. Only
three patients had both a calcium intake above 1200 mg
and a serum 25-OHD3 level above 75 nmol/L (Figure 2).
Five patients had secondary hyperparathyroidism, of
which four were newly diagnosed (Table 2). Hyperparath-
yroidism was secondary to renal insufficiency in three
cases and to low calcium intake in two cases. We found 14
patients with renal insufficiency, of which 6 were newly
diagnosed. Three patients were known with hyperthy-
roidism, 1 new case of exogenous hyperthyroidism and 1
new case of hypothyroidism was detected. One new case
of lactose intolerance was diagnosed. Further contributors
included anorexia nervosa in 2 women, documented
hypogonadism in one men, pulmonary diseases in 5
patients (chronic obstructive lung disease and asthma),
alcohol abuse in 4 men, inflammatory rheumatic diseases
in 3 patients (2 with rheumatoid arthritis and 1 with giant
cell arteritis) and 3 with severe immobility. Most of these
patients did not receive preventive measures for oste-
oporosis prior to the fracture and were thus not recog-
nized as having a contributor to secondary osteoporosis
before the fracture occurred.
Other laboratory abnormalities that required further
exploration were found in 14 patients (18 abnormalities
in total), including exogenous hypervitaminosis D (n =
1), hypercalciuria (n = 3), TSH outside normal ranges (n
= 13) and low serum testosterone in one men (Table 3).
Among the 9 patients being treated for hypothyroidism,
one was over-treated while three were under-treated based
on abnormal serum TSH levels. Among the 3 patients
being treated for hyperthyroidism, two were under-treated
while one was over-treated.
According to the Dutch guideline for osteoporosis 54
patients had clinical bone-related risk factors for fractures
in addition to their current fracture (Table 4). A history of
an additional clinical fracture after the age of 50 was
present in 31 patients (two with a previous clinical spineBMC Musculoskeletal Disorders 2008, 9:109 http://www.biomedcentral.com/1471-2474/9/109
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fracture). Additionally, 12 had a mother that had suffered
one or more fractures, 3 were severely immobilised, and
23 had a low body weight (60 ≤kg). One bone-related risk
factor was found in 41 patients, 2 in 12 and 3 in one
patient. According to the Dutch guideline for fall preven-
tion, we found fall related risk factors in 79 of the patients:
22 patients had one risk factor, 21 had two risk factors,
and 36 had more than two risk factors. An overlap
between clinical bone related risk factors and fall related
risk factors was present in 45 patients. The prevalence of
clinical bone-related and fall-related risk factors was simi-
lar between patients that had documented contributors
secondary osteoporosis and those who did not (50% ver-
sus 59% for clinical bone related risk factors and 79% ver-
sus 84% for fall-related risk factors for fractures).
VFA could be performed for 93 patients. Lateral spine
images were not available in 7 cases due to severe scoliosis
or other technical difficulties such as positioning patients
with humerus fracture on the DXA table. On VFA, 57% of
patients had a MVD, 31% had more than one MVD and
31% had moderate and severe MVD.
The 57 patients with contributors to secondary osteoporo-
sis were older (71 versus 64 yrs, p < 0.01) (Table 1). They
had more of some fall risks (multi-medication use (13
Table 1: Characteristics of the patient population (N = 100)
Variable 
Median+/-SD
All patients Women Men Fragility 
fracture
High energy 
trauma
With 
contributors
Without 
contributors
Number 100 73 27 80 20 57 43
Women/men (n) 73/27 na na 66/14 7/13** 40/17 33/10***
Caucasian 
ethnicity (n)
97 94 27 79 18 55 42
Age (years) 68 ± 10 70 ± 9 62 ± 8* 69,1 ± 9 63.3 ± 9** 71 ± 10 64 ± 7***
Weight (kg) 66 ± 13 63 ± 13 73 ± 11* 65,4 ± 14 68.8 ± 11 64 ± 14 69 ± 11
Spine T-score -2.88 ± .91 -2.94 ± 0.79 -2.73 ± 1.17 -2.9 ± 0.92 -2.8 ± 0.83 -2.85 ± 0.97 -2.93 ± 0.82
Hip T-score -1.92 ± 0.9 -2.13 ± 0.92 -1.37 ± 0.70* -2 ± 0.87 -1.6 ± 1.09 -2.1 ± 1.00 -0.66 ± 0.63***
Hip Z-score -1.92 ± 0.8 -0.57 ± 0.85 -0.89 ± 0.73 -0.62 ± 0.85 -0.83 ± 0.72 -0.66 ± 0.97 -0.66 ± 0.63
BMD spine
(g/sq cm)
0.772+/- 0.100 0.756 ± 0.085 0.810 ± 0.130* 0.765 ± 0.103 0.795 ± 0.094 0.776 ± 0.109 0.766 ± 0.091
BMD hip(g/sq cm) 0.718+/- 0.395 0.676 ± 0.115 0.825 ± 0.107* 0.700 ± 0.116 0.779 ± 0.160** 0.695 ± 0.143 0.749 ± 0.106
Calcium 
intake(mg/day)
852 ± 432 828 ± 448 915 ± 389 851 ± 467 854 ± 266 744 ± 343 993 ± 497***
Serum 25OH 
vitamin D (nmol/L)
66 ± 53 67 ± 60 63 ± 28 63 ± 57 75 ± 30 42 0
Creatinine 
clearance (ml/min)
67 ± 23 62 ± 20 65 ± 23 65 ± 23 74 ± 26 45 ± 18 82 ± 24***
Fracture after fall 
from standing 
height (n)
80 66 14 na na 45 35
N of contributors 
(n)
86 62 24 70 16 na na
N with 
contributors (n)
57 40 17 45 12 na na
N with bone-
related fracture 
risks
54 42 12 44 10 33 21
N with fall-related 
fracture risks
79 57 22 65 14 46 33
Time Go Up and 
Go (min)
8.6 ± 7.9 8.4 ± 8.0 8.9 ± 8.0 8.2 ± 8.0 9.8+/-8.0 8.1+/-8.6 9.2+/-7.1
N with MVD 
<0.80 
(n/n measured)
53/93 35/66 18/27 42/73 11/20 36/54 17/39***
N with MVD 
<0.75
29 22 7 24 11 19 10
*p < 0.05 women vs. men, ** p < 0.05 between fragility fracture and high-energy trauma, *** p < 0.05 between group with and without contributor, 
Na: not applicableBMC Musculoskeletal Disorders 2008, 9:109 http://www.biomedcentral.com/1471-2474/9/109
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versus 3, p < 0.05), restricted activities of daily living (34
versus 15, p < 0.05) and disturbed vision (13 versus 3, p <
0.05) (Table 4)). They had lower calcium intake (744 ver-
sus 993 mg, p < 0.05) (Table 1) and more MVD (67% ver-
sus 44%, p < 0.05, OR: = 2.6, 95% CI: = 1.1–6.0) (Figure
3).
In contrast, the proportions of women (70 versus 77%)
and of patients with fragility fractures (79 versus 81%)
were similar between patients with and without contribu-
tors. There were also no differences in the prevalence of
bone-related clinical risks (59 versus 50%).
Based on the FRAX tool, patients with contributors had a
higher calculated absolute 10-year risk for major (16.5 vs.
9.9%, p < 0.01) and for hip fractures (6.9 vs. 2.4%, p <
0.01).
Compared to patients with a high-energy trauma, patients
with fragility fractures were older (69 versus 63 years), had
better activities of daily living (43 versus 16 patients), and
more osteoarthritis (44 versus 4 patients) (Table 1 and 3).
Discussion
In the 100 patients older than 50 years presenting with a
recent clinical fracture and osteoporosis and referred by
the surgeons to the rheumatologists in collaboration with
the endocrinologists the prevalence of contributors to sec-
ondary osteoporosis was high: almost two out of three
patients had one or more contributors most of which were
correctable.
Our results show that many patients (27%) had known
contributors to secondary osteoporosis, a percentage sim-
ilar to that of Tannenbaum et al. in women with postmen-
opausal osteoporosis who were seen in an osteoporosis
referral centre (32%) [3]. The categories of known con-
tributors to secondary osteoporosis were globally similar
as reported by Tannennbaum [3] (endocrine, gastrointes-
tinal and inflammatory rheumatic and pulmonary dis-
eases, severe immobility, alcohol abuse). One exception
was glucocorticoid users who are presumably frequently
referred to an osteoporosis clinic, but were not repre-
sented in our group of patients. In contrast to Tannen-
baum, we performed the laboratory test set also in
patients with already known contributors and 20 addi-
tional contributors were diagnosed in 20 patients (mainly
low 25-OHD3, n = 14). Presumably none of the patients
with known contributors had received attention in the
context of osteoporosis, as none had osteoporosis treat-
ment or calcium and vitamin D supplements.
In the other, presumably healthy patients without known
contributors, laboratory testing identified newly diag-
Table 2: Contributors to secondary osteoporosis identified in men and women >50 years with a recent clinical fracture (N = 100)
Contributors Total Known Newly diagnosed Fragility Fracture 
(N = 80)
High-energy trauma 
(N = 20)
Endocrine disorders
Serum 25-OHD3 s ≤50 nmol/l 42 0 42 37 5
Hyperparathyroidism secondary to low calcium 
intake
20 2 1 1
Hyperthyroidism 3 3 0 3 0
Hypogonadism (in men) 1 1 0 0 1
Anorexia nervosa (in women) 2 2 0 2 0
Diabetes mellitus 5 5 0 4 1
Gastrointestinal disorders
Lactose intolerance 1 0 1 0 1
Connective tissue disorders
Rheumatoid arthritis 2 2 0 1 1
Giant-cell arteritis 1 1 0 1 0
Renal disorders
Renal insufficiency without secondary 
hyperparathyroidism
11 5 6 7 4
Renal insufficiency with secondary hyperparathyroidism 3 3 0 3 0
Miscellaneous
Severe immobility 3 3 0 3 0
Pulmonary diseases 5 5 0 4 1
Medication and life style
Exogenous hyperthyroidism 1 0 1 1 0
Alcohol abuse 4 4 0 2 2
Total number of contributors (N = 86) 86 34 52 69 17
Total number of patients with contributors to 
osteoporosis (N = 57)
57 27 50 45 12BMC Musculoskeletal Disorders 2008, 9:109 http://www.biomedcentral.com/1471-2474/9/109
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nosed contributors to secondary osteoporosis in 30 more
patients, mostly vitamin D deficiency and renal disorders.
The number of patients with newly diagnosed contribu-
tors (50%) was higher than reported by Tannenbaum et
al. (33%) and concerned mainly vitamin D deficiency,
secondary hyperparathyroidism (to renal insufficiency
and to low calcium intake), malabsorption and exoge-
nous hyperthyroidism [3]. In contrast to Tannenbaum, we
performed TSH not only in patients with a history of thy-
roid diseases, but in all patients, and were able to diag-
nose one new case of hypothyroidism.
Vitamin D status could not be identified by history,
despite including four specific questions regarding vita-
Calcium intake and serum serum levels of 25OHD3 Figure 2
Calcium intake and serum serum levels of 25OHD3. Only 3 patients had sufficient intake of calcium and normal serum 
levels of 25-OHD3.
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min D intake. It has been shown that there is only a mod-
est relation between reported vitamin D intake from an
extensive dietary questionnaire and serum levels of 25-
OHD3 [30]. In our study a wide spectrum of levels of
serum 25-OHD3 were found, from severely deficient to
normal. There is still no consensus about how much vita-
min D supplements are required to normalise serum lev-
els. Some propose a unique dose of 800 IU/day together
with 1000–1200 mg calcium/day to achieve 50 nmol/L
[31,32]. Others state that a unique dose of 800–1600 IU/
day would normalize serum levels to >75 nmol/L [33,21].
As patients with low serum levels of 25-OHD3 require, at
least temporarily, high doses of vitamin D supplements
while those with normal levels require less or none [34],
measuring serum 25-OHD3 levels is helpful in patients
with osteoporosis in order to decide about appropriate
vitamin D supplementation [3].
The calcium homeostasis was further compromised by the
low calcium intake (<1200 mg/day) in most patients,
resulting in secondary hyperparathyroidism in 2, and only
3% of the patients had both adequate calcium intake and
vitamin D status. Correcting these combined deficiencies
has been demonstrated to reduce fracture risk, at least in
institutionalized elderly women [35] and to reduce the
risk of falls [36]. Calcium and vitamin D supplementation
are thus needed in most patients presenting with a frac-
ture and osteoporosis. However, supplementation with
calcium and vitamin D alone is an insufficient measure in
patients with osteoporosis, as drug therapy for osteoporo-
sis has been shown to reduce the risk of fractures on top
of correcting such deficiencies. Our data, together with
those of Edwards et al. [6] indicate that calcium and vita-
min D deficiency is frequently present in patients present-
ing with a fracture, and that these deficiencies need to be
identified and corrected.
Interestingly, the presence of contributors was similar
between women and men, and between patients with
fractures associated with low or high-energy trauma, sug-
gesting that evaluation for secondary contributors is indi-
cated in women and men and after low or high-energetic
trauma.
An additional 14 patients had laboratory abnormalities
that required further investigation, mainly hypercalciuria,
uncontrolled treatment of thyroid disorders and low tes-
Table 3: Laboratory abnormalities that required further 
exploration in men and women more than 50 years of age with a 
recent clinical fracture (N = 100)
Laboratory abnormality Total
Exogenous hypervitaminosis D (>220 nmol/l) 1
Hypercalciuria in 24 hours urine 3
TSH 0.4–3.5 mU/L 13
- >3.5 mU/L 10
- treated hypothyroidism 9
-TSH <0.4 mU/L 1
-TSH >3.5 mU/L 3
- treated hyperthyroidism 3
-TSH >3.5 mU/L 1
-TSH <0.4 mU/L 2
Serum testosterone in men <12 nmol/L (one measurement) 1
Total number of patients 14
Table 4: Clinical risks for fractures recorded in patients with a recent clinical fracture according to the Dutch guidelines
CLINICAL RISKS OF FRACTURE Total Women Men Fragility fracture High trauma Contributors No contributors
Numbers of patients 100 73 27 80 20 57 43
BONE RELATED RISK FACTORS 54 42 12 44 10 33 21
History of clinical fracture after 50 years 31 23 8 25 6 19 12
History of clinical vertebral fracture 2 1 0 1 0 1 0
Mother with fracture 12 9 3 10 2 8 4
Low body weight (<60 kg) 23 20 3 18 5 15 8
Severe immobility 3 3 0 3 0 3 0
Glucocorticosteroids user 0 0 0 0 0 0 0
FALL RELATED RISK FACTORS 79 57 22 65 14 46 33
Mobility: Time Get up and Go test 24 21 3 20 4 12 12
Previous falls: 2 or more falls in the 
previous year
27 22 5 23 4 15 12
Medication use 
(benzodiazepines, antiepileptics)
16 14 2 14 2 13 3
Low activities of daily living 49 38 11 43 16* 34** 15
Osteoarthritis 48 40 8 44 4* 25 23
Snellen score-visual acuity less than 0.4 16 8 8 14 2 13 3
Urinary incontinence 19 17 2 19 0 13 6
*p < 0.05 between fragility fracture and high-energy traum fracture, **p < 0.05 between groups with and without contributorsBMC Musculoskeletal Disorders 2008, 9:109 http://www.biomedcentral.com/1471-2474/9/109
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tosterone (in one man). Hyperthyroidism, whether
endogenous or exogenous, can increases bone turnover
and contributes to secondary osteoporosis [37,38].
Hypothyroidism on the other hand increases the risk of
fractures through low bone turnover if untreated or high
bone turnover if over treated [39]. Thus fine-tuning thy-
roid treatment is indicated. The same is probably true for
patients with hypercalciuria in whom thiazides are indi-
cated [40], and for hypogonadism in men that can be
treated with testosterone supplementation [41], although
no fracture prevention data are available in these condi-
tions.
Therefore, measuring serum 25-OHD3, calcium in 24
hours urine, serum creatinine, TSH, PTH as proposed by
Tannenbaum et al. is indicated in patients with oste-
oporosis and a recent clinical fracture, and enabled us to
identify 47 (96%) newly diagnosed contributors and 13
of the 14 laboratory abnormalities [3]. As many patients
had endocrine diseases, collaboration with endocrinolo-
gists appeared to be highly valuable for diagnosis and
treatment.
The prevalence of clinical bone-related fracture risks in
postmenopausal women, as evaluated by the Dutch
guidelines, was similar between patients with and without
documented contributors to and it contributed to further
specify the risk for fractures.
Nearly 80% of patients had fall-related risk factors for frac-
tures, as reported by others [16]. Although it has not been
shown until now that fall prevention strategies itself can
prevent fractures, they reduce the risk of falls. [42] A
multidisciplinary, multifactorial intervention program
reduces postoperative falls and injuries after femoral neck
fracture and are therefore applied in our ongoing preven-
tion program [43].
An interesting finding was the prevalence of MVD which
was more than twice as high among patients with docu-
mented contributors for secondary osteoporosis com-
pared to those without contributors, in spite of similar
low BMD in both groups. MVDs, that are related to future
fracture risk independent of BMD [11], reflect bone failure
independently of BMD and thus indicate other mecha-
nisms of bone's decreased resistance to fracture than low
BMD, such as changes in the bone turnover, alterations in
micro architecture of bone and deficient mineralization,
especially in the context of the high prevalence of calcium
and vitamin D deficiency.
Prevalence of MVD defined according to the grading of Genant et al. in patients with contributors to secondary osteoporosis  and in patients without contributors Figure 3
Prevalence of MVD defined according to the grading of Genant et al. in patients with contributors to second-
ary osteoporosis and in patients without contributors.
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In several recent publications differential diagnosis and
search for contributors to secondary osteoporosis is advo-
cated [44,45]. Only limited data are available about col-
laboration between surgeons and internists in taking care
for osteoporosis in patients presenting with a fracture.
Some initiatives were very successful [46], but in most
instances the collaboration is failing [47]. This study indi-
cates that such collaborations add to better treatment of
patients with a clinical fracture.
This study has several limitations. Smoking history, which
is part of the WHO FRAX tool, was not recorded as it is not
part of the Dutch guideline. The sample size was relatively
small, but the strength of the study was that consecutive
patients were evaluated showing that even in a small
group many contributors to secondary osteoporosis could
be diagnosed. Some laboratory abnormalities needed fur-
ther exploration, but were not followed up and so no def-
inite diagnosis could be reported in these patients. VFA
has several limitations. Not all vertebrae could be meas-
ured, mainly at the upper thoracic level. Identifying
patients with MVD by VFA requires additional X-rays to
differentiate deformities due to other conditions, such as
Scheuerman's disease, degenerative changes or non-oste-
oporotic short vertebral height. However, the method has
a high negative predictive value in predicting the absence
of vertebral fractures on X-rays [27]. Another limitation is
that only patients with BMD-osteoporosis were included.
Most patients with a fracture have no BMD-osteoporosis.
The results of our study suggest that documentation of the
prevalence of contributors to secondary osteoporosis
should also be studied in patients with a clinical fracture
without BMD osteoporosis.
Conclusion
We conclude that more than one in two patients present-
ing with a clinical vertebral or non-vertebral fracture and
BMD-osteoporosis have secondary contributors to oste-
oporosis, most of which were correctable. Identifying and
correcting these associated disorders will enhance treat-
ment effect aimed at reducing the risk of subsequent frac-
tures in patients older than 50 years.
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